No Data
There's Reason For Concern Over Guangdong Jiaying Pharmaceutical Co., Ltd's (SZSE:002198) Massive 26% Price Jump
Jiaying Pharmaceutical: Report for the third quarter of 2024
Guangdong Jiaying Pharmaceutical (002198.SZ): The net income for the first three quarters was 2.8733 million yuan, a year-on-year decrease of 88.46%.
Jiaying Pharmaceutical (002198.SZ) announced its third quarter report for 2024 on October 30th. The company achieved revenue of 0.26 billion yuan in the first three quarters of the year, a decrease of 31.18% year-on-year; the net income attributable to shareholders of the listed company was 2.8733 million yuan, a decrease of 88.46% year-on-year; the net income attributable to shareholders of the listed company after deducting non-recurring gains and losses was -1.879 million yuan; basic earnings per share were 0.0057 yuan.
Guangdong Jiaying Pharmaceutical (002198.SZ): Orient, a shareholder owning more than 5% of the shares, plans to reduce its shareholding by no more than 1% of the company's shares.
Guangdong Jiaying Pharmaceutical (002198.SZ) announced on October 16 that shareholder Orient currently holds 57,223,000 shares of the company (accounting for 11.28% of the total share capital). Orient plans to reduce its shareholding by 5,075,098 shares (not exceeding 1% of the total share capital) through centralized competitive bidding trading within three months after fifteen trading days from the date of this shareholding reduction plan announcement.
Guangdong Jiaying Pharmaceutical Co., Ltd's (SZSE:002198) Financials Are Too Obscure To Link With Current Share Price Momentum: What's In Store For the Stock?
Jiaying Pharmaceuticals: Semi-Annual Report 2024
Guangdong Jiaying Pharmaceutical (SZSE:002198) Delivers Shareholders Favorable 9.6% CAGR Over 3 Years, Surging 16% in the Last Week Alone
